Syngoi produces pure synthetic linear DNA using an optimized enzymatic manufacturing process, enabling reliable and affordable genetic medicines for advanced therapies. Their technology delivers high‑quality synthetic DNA that serves as a fundamental asset in developing next‑generation treatments, offering a cost‑effective alternative to traditional DNA synthesis methods.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced therapies such as gene editing, cell therapies, and mRNA vaccines require high‑purity linear DNA, but traditional chemical synthesis is costly, low‑yield, and can introduce impurities that affect product safety and efficacy.
Solution
Syngoi uses an optimized enzymatic manufacturing process to produce linear synthetic DNA with consistent high purity and reduced cost. The enzymatic approach enables scalable production of long DNA strands while maintaining sequence fidelity, making the material suitable for clinical‑grade genetic medicines. By delivering DNA as a reliable, affordable raw material, Syngoi supports developers in accelerating pre‑clinical and clinical programs without the supply constraints of conventional synthesis methods.
Target Audience
Primary customers are biotech companies and research organizations developing gene‑editing tools, cell‑based therapies, and mRNA vaccine platforms that require high‑quality linear DNA at scale.
Features
- Enzymatic synthesis platform that generates long, linear DNA strands with high sequence accuracy
- Production workflow designed for scalability and cost efficiency compared to traditional chemical synthesis
- Purity control processes delivering clinical‑grade DNA suitable for gene editing, cell therapy, and mRNA vaccine applications
- Flexible manufacturing that can be tailored to specific sequence lengths and modifications required by advanced therapy projects
- Integrated quality testing to ensure batch‑to‑batch consistency and regulatory compliance